(Q40642031)

English

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

scientific article published on January 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset). (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Raymond F. Schinazi

9

object named as

Raymond F Schinazi

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

7

object named as

Guoen Shi

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

3

object named as

Hangchun Zhang

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

5

object named as

Sena Garber

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

4

object named as

Lee Bacheler

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

author name string

Romas Geleziunas

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Karen Gallagher

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Jing-Tao Wu

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Michael J Otto

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Susan Erickson-Viitanen

10

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

publication date

1 January 2003

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Antiviral Chemistry & Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

49-59

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

HIV therapy: managing resistance

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400105

21 January 2018

Identifiers

10.1177/095632020301400105

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40642031&oldid=2117515963"